Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 6/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24633710 | 1.00 | MDM4 (0.47) | MDM4TP53CASP3KMT2ATNF | |
| SCHEMBL25260680 | 1.00 | MDM4 (0.47) | MDM4TP53CASP3KMT2ATNF | |
| SCHEMBL25657544 | 0.96 | MDM4 (0.46) | MDM4TP53CASP3KMT2ATNF | |
| SCHEMBL24633712 | 0.90 | MDM4 (0.55) | MDM4TP53CASP3KMT2ATNF | |
| SCHEMBL29855105 | 0.90 | MDM4 (0.55) | MDM4TP53CASP3KMT2ATNF | |
| SCHEMBL25177902 | 0.90 | MDM4 (0.55) | MDM4TP53CASP3KMT2ATNF | |
| SCHEMBL25216631 | 0.90 | MDM4 (0.55) | MDM4TP53CASP3KMT2ATNF | |
| SCHEMBL20825486 | 0.89 | MDM2 (0.42) | MDM4TP53CASP3TNFTLR2 | |
| SCHEMBL20825490 | 0.89 | MDM2 (0.42) | MDM4TP53CASP3TNFTLR2 | |
| SCHEMBL8138543 | 0.87 | KMT2A (0.51) | MDM4TP53CASP3KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4444728-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | Pretzel Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107487-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | LONP1, NLN, ACAT1 | MDM4 2078/4885TP53 282/4885CASP3 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.